Anzeige
Mehr »
Login
Dienstag, 19.03.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Der Zug verlässt den Bahnhof - Umringt von potenziellen Käufern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0YD8Q | ISIN: US58933Y1055 | Ticker-Symbol: 6MK
Tradegate
18.03.24
20:50 Uhr
111,60 Euro
-0,20
-0,18 %
1-Jahres-Chart
MERCK & CO INC Chart 1 Jahr
5-Tage-Chart
MERCK & CO INC 5-Tage-Chart
RealtimeGeldBriefZeit
111,60112,0018.03.
111,40112,0018.03.

Aktuelle News zur MERCK & CO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAstraZeneca/Merck's Lynparza approved by SMC to treat advanced prostate cancer in Scotland4
FrNewly Diagnosed Cervical Cancer Patients - Merck's Blockbuster Drug Keytruda Plus Chemoradiotherapy Improves Overall Survival7
FrMerck's Keytruda excels in cervical cancer trial, showing an ability to extend lives. Will a broader FDA approval follow?6
FrMerck's Keytruda claims digital marketing crown, holding off challenges from AstraZeneca, BMS8
FrMerck's KEYTRUDA shows postivie Phase 3 results in cervical cancer study3
FrMerck's Keytruda combo succeeds in late-stage trial for cervical cancer treatment4
FrMerck hits main goal for Keytruda in late-stage trial for cervical cancer3
DoDividendenbekanntmachungen (14.03.2024)6.560 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ABRDN PLC  GB00BF8Q6K64  0,073 GBP  0,0853 EUR  ABRDN PLC ADR  US00108N1000  0,3203 USD  0,2925 EUR  ACCO BRANDS CORPORATION  US00081T1088  0...
► Artikel lesen
MiMerck reveals plans to develop newer HPV shots6
MiMerck to start trials investigating single dosing regimen of HPV vaccine4
MiMerck to study single-dose regimen of HPV vaccine Gardasil 94
MiPearl Bio and Merck partner for discovery of cancer therapies4
12.03.Ideaya Biosciences Enters Clinical Trial Collaboration & Supply Agreement with Merck5
12.03.Ideaya gains after clinical trial pact with Merck3
12.03.IDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With Merck's KEYTRUDA In Endometrial Cancer290KENILWORTH (NJ) (dpa-AFX) - IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced Tuesday that it has entered into a clinical trial collaboration and supply agreement...
► Artikel lesen
12.03.IDEAYA and Merck team up for cancer drug trial5
12.03.IDEAYA Biosciences, Inc.: IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with Merck's KEYTRUDA (pembrolizumab) in Patients with Endometrial Cancer83Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cancer...
► Artikel lesen
11.03.Dow Jones Leader Merck, Square Stock Are In Or Near Buy Zones In Today's Stock Market15
11.03.Societe General cuts Merck to sell, cites Keytruda patent expiry7
11.03.Moderna rises on new skin cancer treatment trial with Merck, analysts say30
Seite:  Weiter >>
679 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
6,2,17